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Chronic nonmalignant pain is a common problem that is difficult to treat.  Opioids are 
often used to treat chronic pain, but a significant potential for misuse exists.  Adding to this 
difficulty is the problem of differentiating between untreated pain and drug-seeking behavior.  A 
number of strategies are recommended by different clinical guidelines to help the clinician 
reduce the potential for opioid misuse among chronic pain patients.  These include treatment 
agreements, urine drug testing, case management, referral to pain specialists, and prescription 
drug monitoring programs (PDMPs).  The purpose of this study was to evaluate the evidence for 
these strategies in reducing the prevalence of opioid misuse among chronic nonmalignant pain 
patients.  A systematic review was performed and a total of 22 articles were reviewed in detail, 
of which 5 were included in the final review—1 for treatment agreements, 2 for urine drug 
testing, 0 for case management, 1 for pain specialists, and 1 for PDMPs.  Results showed that 
treatment agreements are associated with a prevalence of opioid misuse of 13% after five years, 
urine drug testing decreases the prevalence of prescription drug abuse by 8.8% and illicit drug 
use by 6%, specialized pain treatment programs reduce reliance on opioid medications as well as 
indices of addiction, and that the presence of a PDMP slows the rate of increase in state supply 
of opioids.  Proactive PDMPs are associated with further slowing of the rate of increase when 
compared to reactive PDMPs.  In conclusion, research is lacking that evaluates the effectiveness 
of these strategies, and some of the research that exists is of fair or poor quality.  Inferences can 
be made by evaluating the effectiveness of these interventions in other populations, but the 
external validity when applied to chronic nonmalignant pain populations is difficult to ascertain.  
Much further research is needed to evaluate the effectiveness of these strategies to reduce the 
prevalence of opioid misuse among chronic pain patients.  
 2 
Introduction 
Chronic nonmalignant pain is a common problem that is difficult to treat.  Studies have 
estimated the prevalence of chronic pain at anywhere from 19% to 46.5% in the general 
population.
1,2
 Not all persons who report chronic pain will have pain severe enough to see a 
healthcare provider, but this pain may still be debilitating.  Chronic pain affects many aspects of 
life, including ability to function and psychological health as well as social and economic well-
being.  Because chronic pain affects so many aspects of life, treatment of chronic pain often 
requires a multidisciplinary approach which addresses issues such as pain status, functional 
status, mental health, ability to sleep, and social relationships.
3 
Opioids are often used for pain control in the treatment of chronic pain patients.  
However, the potential (and desire) to misuse opioids in clinical settings and the general 
population is high.  Results from the National Survey on Drug Use and Health show that abuse 
of OxyContin (a long-acting opioid) has increased from 1.9 million abusers in 2002 to 3.1 
million in 2004 (an increase of 63% in two years), with the largest increase occurring in young 
adults aged 18 to 25.
4
 Researchers are learning more about this increasing trend by identifying 
risk factors for misuse from patient demographic data.  These findings will allow providers to 
identify high risk populations and increase vigilance accordingly. 
Many different groups
 
have published guidelines to assist primary healthcare providers in 
treating chronic pain.  These groups include health care agencies such as Department of Veterans 
Affairs,
5
 quality improvement organizations such as the Institute for Clinical Systems 
Improvement,
3
 and regulatory agencies such as the Federations of State Medical Boards and 
many of its members, including the North Carolina Medical Board.
6
  The guidelines recommend 
that certain strategies be implemented to improve outcomes related to pain and to reduce the risk 
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of opioid misuse.  Several of these strategies include treatment agreements (otherwise known as 
pain contracts), regular urine drug testing (to determine (a) whether the patient is actually taking 
the prescribed opioid and (b) whether the patient is abusing illicit drugs in addition to the 
prescribed opioid), case management (to reduce the risk of misuse as well as addressing social 
aspects of patient care), utilization of a prescription drug monitoring program when available, 
and when management has become problematic, referral to a specialized pain clinic.   
Evidence for the benefits of these strategies on patient outcomes is limited.  These 
strategies are recommended largely based on expert opinion, with the expectation that they will 
improve important outcomes--including patient-centered outcomes (pain control, functional 
status, mental health status) as well as public health outcomes (reduction of opioid misuse).  
While some of these strategies explicitly focus on improving the patient-centered outcomes, 
others of these strategies are primarily implemented to protect the physician as well as the 
society from giving prescription drugs to patients who misuse them.  The goal of this systematic 
review is to review the existing evidence for these strategies (urine drug testing, treatment 
agreements, case management, specialized pain clinics, and prescription monitoring programs) in 




Burden of Suffering 
Chronic nonmalignant pain places a large disease burden on the population.  A survey of 
46,394 participants over 18 years in 16 different European countries found the prevalence of 
chronic pain to be 19%.
2
 Another survey of 2012 Canadians found the prevalence to be 29% in 
the general population.
7
 The social costs of chronic pain are high as well: among the subjects 
 4 
with chronic pain in the Canadian sample, almost one-half were unable to attend social and 
family events.
7
 A cross-sectional survey of 28,902 working adults in the United States found that 
13% of the total workforce experienced a loss in productive time during a 2-week period due to a 
common pain condition (headache, back pain, arthritis pain, or other musculoskeletal pain). The 
loss in productive time was estimated to cost 61.2 billion dollars per year. Three quarters of the 
lost productive time was explained by reduced performance at work rather than work absence.
8
 
The authors comment that, with this study design, they may have underestimated current lost 
productive time among those with persistent pain problems (e.g. chronic daily headache), 





Types of Pain and Non-opioid Treatment Options 
Chronic pain conditions envelop a wide variety of diseases with differing 
pathophysiology and are conventionally differentiated by subtype of pain.  Subtypes include 
neuropathic pain (including diagnoses such as diabetic neuropathy, complex regional pain 
syndrome, HIV sensory neuropathy, metabolic disorders, phantom limb pain, Parkinson's 
disease, multiple scleroses, myelopathies, and post-stroke pain), muscle pain (including 
fibromyalgia, myofascial pain syndrome, and trauma), inflammatory pain (inflammatory 
arthropathies, infection, post-operative pain, and tissue injury), and mechanical/compressive pain 
(low back pain, neck pain, visceral and specific musculoskeletal pain).
3
 These conditions are 
similar in that they lead to debilitating pain and decline in functional status and mental health.   
A variety of options exist for the treatment of chronic nonmalignant pain.  Medicines to 
alleviate pain can be prescribed by a healthcare provider, and these are described in detail below. 
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Also, alternative therapies are common in chronic pain patients, presumably because these 
patients are not satisfied with the benefits of traditional medicine alone.  Acupuncture is one of 
the oldest of these health practices and has led to the popularity of alternative medicine in our 
culture.  It involves stimulation of tissue with fine needles to restore the normal flow of energy, 
and has been studied with scrutiny.
3
 The 1997 National Institutes of Health consensus statement 
has supported acupuncture’s use as an adjunct therapy for numerous pain conditions.9 Other 
avenues of treatment for chronic pain include biofeedback, osteopathic manipulation, 
chiropractic, cognitive behavioral techniques, psychotherapy, massage, and music therapy.   
Alternative medicine use is more prevalent among chronic pain patients than healthcare 
providers may expect.  One survey of 110 patients with chronic tension-type headache reported 
the prevalence of past use of alternative medicine at 40% of patients (22.7% in the last year).  
Most of the patients that used alternative therapies did so for the alleviation of headaches 
(77.3%), and almost 60% of these patients did not inform their doctor about the use of alternative 
therapies.
10
 Many different alternative therapies exist, and medical providers must be proactive 
in obtaining information about their patients’ practices. 
Pharmacologic options for treating chronic pain are numerous and depend on the type of 
pain that the patient exhibits.  Two decades ago, most chronic pain was treated with non-
steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and sometimes opioids.
3
 Today a 
wide variety of classes of medicines are used for different subtypes of chronic pain.  
Acetaminophen can be used for mild to moderate pain, and is generally very safe except in 
patients with advanced liver disease.  NSAIDs are indicated for the treatment of mild to 
moderate non-neuropathic pain, but increase the risk of gastro-intestinal bleeds, renal 
insufficiency, and even cardiovascular disease.  This limits their long-term use.  Tri-cyclic 
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antidepressants (TCAs) are a preferred initial therapy for neuropathic pain, especially in the 
setting of co-existing insomnia, anxiety or depression.   Side-effects include sedation, dry mouth, 
constipation, urinary retention, and possible cardiac arrhythmias.  Other antidepressants (with 
better risk profiles) are also indicated for the treatment of neuropathic pain, but without the same 
effectiveness as the TCAs.  Anticonvulsants, such as carbamazepine, lamotrigine, and 
gabapentin are also indicated for certain causes of neuropathic pain.
3
 Recent advances in the 
treatment of chronic pain have made the classification of pain subtype an imperative for 
providers. 
 
Effectiveness of Opioids for the Treatment of Chronic Pain 
Opioids have demonstrated limited effectiveness for pain control in the treatment of 
chronic pain.   A well-done randomized trial that examined the use of oral morphine for chronic 
non-cancer pain of musculoskeletal or soft tissue origin found that a nine-week course of oral 
morphine improves pain scores with a low risk of addiction.
11
 A meta-analysis of opioids in 
chronic non-cancer pain (80% of patients with nociceptive pain, 12% with neuropathic pain, 7% 
with fibromyalgia, and 1% mixed) also found that opioids lead to a decrease in pain.
12
 However, 
a recently published systematic review of the effectiveness of opioids for chronic low back pain 




The effectiveness of opioids in the improvement of functional status is more 
controversial.  The randomized controlled trial mentioned above found that opioids did not 
provide any significant improvement in functional or psychosocial outcomes.
11
 Also, the meta-
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analysis of opioids in chronic non-cancer pain found that opioids had less effectiveness in the 
improvement of functional status than other drugs (diclofenac was specifically mentioned).
12
 
In many of the trials in both reviews mentioned, patients with a history of addiction are 
excluded from the study, making the results of the reviews apply more to efficacy than to 
effectiveness.  Also, many of the trials did not include measures to evaluate the incidence of 
addiction or opioid misuse, and those that did had short study durations.  In summary, consensus 
exists about the ability of opioids to reduce pain, but the benefits of opioids for other outcomes 
(specifically functional ability and mental health) have not been rigorously established.  This is 
an important distinction, because many authorities on chronic pain consider functional outcomes 
of greater importance than improvements in pain scores.   
 
Adverse Effects of Opioid Therapy 
Opioid therapy for chronic nonmalignant pain entails a high likelihood of adverse effects.  
In a sample of 1009 primary care patients taking opioids for chronic nonmalignant pain, patient 
reported side-effects include constipation (40%), sleeping problems (25%), loss of appetite 
(23%), and sexual dysfunction (18%).
14
 Other adverse effects of opioid therapy include nausea 
and vomiting, sedation, cognitive impairment and respiratory depression.  Many opioids cause an 
elevation in mood (euphoria) and the reduction of emotional distress,
15
 increasing their potential 
for abuse.  Tolerance may occur with opioid use, leading to withdrawal symptoms when 
discontinued.  Concern exists about the possibility of addiction to opioids, characterized by a 
psychological dependence on the use of the substance, which manifests itself in aberrant 
behaviors such as loss of control over drug use, compulsive drug use and continued use despite 
harm.
16




 Whether these addictions are iatrogenic (that is, whether these are new substance 
abuse disorders in opioid naïve patients) is unclear.  
 
Opioid Misuse 
―Misuse‖ is a comprehensive term that includes all unsafe practices relating to the use of 
a certain drug.  Often this requires going against the physician’s explicit instructions for the use 
of the medication.  In the case of opioids, misuse refers to more than just abuse of the drug—it 
includes practices like selling the prescription opioid (i.e. diversion) and using illicit drugs while 
taking the opioid for pain.  Ives et al. have formulated the following definition of opioid misuse: 
negative urine toxicological screening (the patient is not taking their prescription), inconsistent 
urine screening (positive for other opioids not prescribed by the healthcare professional), doctor 
collecting (the patient is receiving prescriptions from multiple providers), evidence of diversion, 
prescription forgery, or urine screening positive for stimulant drugs (cocaine or amphetamine).
17
 
These practices are usually defined and prohibited in the treatment agreement between the 
provider and the patient. 
More commonly encountered than patients with iatrogenic addiction are patients with 
pre-existing substance misuse disorders who present to their provider requesting opioids.  A one 
year prospective cohort study of 196 chronic pain patients showed that strong predictors for 
opioid misuse included self-reported histories of previous alcohol abuse, cocaine abuse, or 
previous drug or alcohol related criminal convictions.
17
 Therefore, one can infer that chronic 
opioid use does not lead to iatrogenic substance abuse disorders, but that opioids are misused 
among the patients with pre-existing substance misuse disorders or behaviors.  Interestingly, 
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gender, race, literacy, disability, and measures of socioeconomic status were not associated with 
misuse in this study.
17
 
The potential for misuse with opioids is significant, since patients may be tempted to 
increase doses either to self-medicate pain or to induce euphoria.  The prevalence of opioid 
misuse among patients at tertiary pain clinics ranges from 3% to 19%.
18
 A systematic review 
found even higher prevalences (up to 24%) of substance abuse and aberrant drug-related 
behavior among the chronic pain patients in the reviewed studies.
13
 Results from the 2004 




Because of the diversion of medication, many of those abusing opioids are probably not 
the same people for whom the prescriptions are being written.  For example, opioid prescription 
misuse is a growing problem in the college community, presumably from diversion of 
medication by those for whom the prescriptions were written.  Estimates of opioid use range 
from 0% at the lowest risk universities to 20% at the highest risk universities.
19
 The 12-month 
prevalence of any non-medical prescription drug use has more than doubled between 1993 
(4.41%) and 2001 (9.97%).
20
 Trends in marijuana use were highly correlated with trends in non-
medical prescription drug use.   
 
Strategies to Reduce Opioid Misuse 
Healthcare providers need tools to mitigate the misuse of prescription opioids.  That is, 
they should prescribe opioids with the reasonable assurance that they are maximizing therapeutic 
benefit to the patient and minimizing harm.  In addition, opioid prescribing is unique in that the 
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potential for harm may not only accrue to the individual patient but also society at large by 
abetting the epidemic of prescription drug abuse.  
This is a difficult task, because restriction of opioids must be balanced with adequate pain 
control.  To complicate matters, drug-seeking behaviors can either be a sign of addiction or they 
can point to self-management of under-treated pain.
21
 Tools that will be evaluated in this review 
include urine drug testing, treatment agreements, case management, specialized pain clinics, and 
prescription monitoring programs.  These tools have two main goals: to improve the outcomes of 
patients with chronic pain,
21
 and to prevent drug-seeking individuals without legitimate pain 
issues from obtaining opioids.  While many different techniques are available to predict drug-
seeking behavior,
22
 distinguishing drug-seeking behavior from legitimate pain can be difficult in 
clinical practice.  In one emergency department study, 22% of patients suspected of drug-seeking 
behavior were ultimately diagnosed with organic pathology.
23
 In light of this diagnostic 
dilemma, these strategies are intended to be applied non-discriminately to any patient presenting 
with chronic pain symptoms.  This review will focus on evidence for the reduction of opioid 
misuse in chronic pain patients, regardless of the legitimacy of the pain. 
 
Treatment Agreements.  Treatment agreements, otherwise known as pain contracts, are 
put in place to set clear boundaries and responsibilities for the chronic pain patient.  The contract 
between the patient and the provider usually is based on four distinct assumptions: the terms and 
consequences for breaching the contract are stated explicitly; the doctor and patient each have 
unique responsibilities; the doctor/patient relationship is a consensual one (rather than 
obligatory) and; both physician and patient are willing and able to negotiate.
24
 A survey of 39 
different contracts from nationally reputed academic medical centers found that most opioid 
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agreements opioid agreements ranged in length from 1 to 10 pages, encompassing a wide variety 
of information.  Most included information about terms of treatment (97%), prohibited behavior 
(95%), and points of termination (92%).  A large proportion of agreements also included 
information about patient responsibilities (85%), education (79%), and additional treatment 
(74%).  Information that was present in only a minority of opioid agreements included 
information about emergency issues (38%), goals (38%), limitations on prescriptions (38%), 
legal considerations (33%), discouraged behavior (31%), and staff responsibilities (18%).
25
 
It can be argued that the opioid agreement is enacted primarily to protect the physician 
from drug seeking behavior and legal consequences of aiding this behavior.  Still, a survey of 
physicians in Wisconsin found that written drug agreements are only utilized by 42% of primary 
care practitioners.
26
 Any evidence that the accountability provided by treatment agreements 
reduces the incidence of opioid misuse by chronic pain patients will encourage more physicians 
to implement this tool.  As of 2001, no standardized validated opioid agreement has been put in 
place,
25
 which may make evaluation of the opioid agreement difficult. 
 
Urine Drug Testing.  Urine drug testing is an important tool for the measurement of 
opioid misuse or illicit drug abuse among chronic pain patients.  Although urine drug testing is a 
measurement tool, it also serves as an intervention tool by providing the patient with 
accountability.  If the patient is periodically screened for evidence of opioid misuse, the 
likelihood that he or she will misuse opioids may decrease.  In this way, urine drug testing serves 
to reinforce the treatment agreement by giving the provider information about the patient’s 
behavior.  Evidence of opioid misuse with urine drug testing may include lack of prescribed 
opioid in urine (indicating that the patient may be diverting or otherwise misusing the opioid) or 
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presence of an illicit drug in the urine (which also constitutes misuse of the opioid and a breach 
of the treatment agreement). 
Abnormal urine screens among chronic pain pains have been remarkably high in some 
studies.  For example, a retrospective analysis of 470 chronic pain patients found that 45% of 
patients had an abnormal urine screens.
27
 Despite the high prevalence of abnormal urine 
screening results, urine screening is relatively underutilized.  The previously mentioned survey 
of physicians in Wisconsin found that urine drug testing is only utilized by 8% of primary care 
practitioners.
26
 If these practitioners feel that they can perceive misuse based on behavioral signs 
alone, they are mistaken.  One study showed that 21% of patients with no behavioral signs of 




Case Management.  Case management is emerging as a new tool for the evaluation and 
effective management of chronic pain patients at high risk for opioid misuse.  Case management 
has been advocated by pain specialists for certain high-risk subpopulations of chronic pain 
patients.
29
 The role of case management has been well established with the use of methadone in 
addiction treatment programs,
30
 but the role in chronic pain patients is relatively unstudied.  
These populations may have similarities in that addicted populations may seek opioids by 
presenting with chronic pain symptoms.  Even in those patients with legitimate chronic pain 
issues, case management could provide a unique opportunity for patient education and 
accountability.  Case managers are in a strategic position to assess whether certain patient 





Pain Specialists.  Specialized pain clinics offer a wide range of expertise and tools to 
treat the chronic pain patient.  Proponents of pain clinics cite a lack of information among 
general practice physicians and a lack of proper facilities for treatment as the reasons for the 
need for more pain clinics.
32
 Goals of specialized pain clinics include decreasing the amount of 
pain the patient experiences, to decrease the amounts and types of medicines that the patient 
uses, to help the patient attain maximal functional status, to decrease the use of medical facilities 
and the associated costs, and to help the patient develop insight into the patient’s situation.33 Two 
out of five of the goals mentioned are concerned with the independence of the patient from the 
medical system, which may be correlated with a reduction of the prevalence of opioid misuse 
among chronic pain patients.  Any evidence that pain clinics are effective in reducing the 
incidence and prevalence of opioid misuse would provide more support for referral to pain 
clinics. 
 
Prescription Drug Monitoring Programs.  Prescription drug monitoring programs 
(PDMPs), or controlled substance reporting systems, represent a public health approach to target 
the reduction of opioid misuse.  As of May 2005, at least 28 states have established or are in the 
process of establishing prescription monitoring programs for controlled substances.
17
 The goals 
of prescription monitoring programs involve education of the public, delivery of information to 
pharmacists and providers, execution of public health initiatives to prevent abuse and diversion, 
and investigation and enforcement of abuse.
34
 However, in the effort to reduce misuse of opioids, 
prescription monitoring programs can have a negative effect on the adequate treatment of 
chronic pain by stigmatizing the patient and placing restrictions on the provider.
34
 Collaboration 
between regulatory and pain management representatives has attempted to address these issues 
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by better defining the balance between diversion and treatment of pain, educating providers as to 




It is important to note that differences exist in the protocols of different PDMPs.  Some 
can be classified as proactive while others are reactive.  Proactive PDMPs analyze data to 
identify and investigate cases, generating unsolicited reports to send to clinicians.  Reactive 
PDMPs respond to requests for investigation from healthcare providers, generating only solicited 
reports for clinicians.
36
 This distinction is important, because the effects of PDMPs in reducing 
the misuse of opioids may vary depending on the organization of the PDMP. 
 
Position Statements and Clinical Guidelines 
The issue of opioids in chronic pain management has generated a great deal of discussion 
among clinicians and public health officials alike.  Many groups have published position 
statements or clinical guidelines to aid the clinician in the treatment of chronic pain.  The 
American Pain Society and the American Academy of Pain Medicine have worked together to 
write a position statement
37
 focusing on the issue of under-treatment of pain.  A position 
statement of the American Medical Association
38
 has the same focus, arguing for the legitimate 
use of prescription drugs for chronic pain.  A statement by the American Society of 
Anesthesiologists reports that opioid misuse, aberrant behavior and diversion are rare among 
chronic pain patients, and that while patient monitoring is important, ―the use of patient contracts 
and/or random blood or urine screening for substances has not been shown to improve 
compliance or reduce diversion.‖39 
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In addition, a number of guidelines exist for the treatment of chronic pain.  Many state 
Medical Boards (e.g. the North Carolina Medical Board
6
) have put forth guidelines as well as 
position statements.  The guidelines of the North Carolina Medical Board support the use of a 
written treatment agreement for high risk patients, including responsibilities of urine/serum 
medication levels screening when requested.  Other guidelines have been published by the 
Institute for Clinical Systems Improvement,
3
 the Veterans Health Administration,
5
 and individual 
researchers.
40,41
 Many of these guidelines recommend the use of treatment agreements, include 




 and pill counts.
40
 These guidelines also 
make provision for referral of high risk patients to a pain or addiction specialist.
3,5
 Most of these 
guidelines support the practice of a thorough history and physical examination to elucidate any 
risk factors for opioid abuse, and to confirm the need for opioid therapy. 
Ideally, those who author guidelines will process the evidence in a systematic way to 
make objective recommendations for clinical practice.  Often, however, authors rely on expert 
opinion when evidence is lacking.  Expert opinion is not necessarily formed systematically, and 
can be swayed by connections with stakeholders.
42
 This has been especially true for guidelines 
concerning chronic pain, as their authors have been susceptible to influences from the 
pharmaceutical companies that produce opioid medications.
43
 The validity of guidelines is 
limited by these potential conflicts of interest as well as the availability of good evidence, and 
they should be scrutinized carefully. 
 
Purpose of this Review 
One of the position statements mentioned recognizes the need for guidelines to 
―distinguish legitimate medical practice from questionable practice.‖37 To what extent are these 
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clinical guidelines based on evidence?  To my knowledge, no systematic review has been done to 
determine the effectiveness of these strategies.  This systematic review will summarize the 
evidence for the current practices aimed at reducing opioid misuse among chronic pain patients: 
treatment agreements, urine drug screening, case management, pain clinics, and prescription 
drug monitoring programs.  The evidence will lead into recommendations for further research as 
well as recommendations for providers and policy makers.   
 
Methods 
The plan for this systematic review was developed through consultation with C. Annette 
DuBard, MD, MPH and Paul R. Chelminski, MD, MPH.  Dr. DuBard is working with 
Community Care North Carolina on a quality improvement initiative targeting the reduction of 
opioid misuse in Wilkes County, North Carolina.  Dr. Chelminski is a faculty member in the 
Department of Medicine at the University of North Carolina-Chapel Hill.  He is an active 
clinician and has published studies on the prevalence of opioid misuse among chronic pain 
patients.   
 
Key Questions 
In this review, I examined the following key questions: 
1.  Do treatment agreements reduce the prevalence of opioid misuse in chronic pain patients? 
2.  Does urine drug testing reduce the prevalence of opioid misuse in chronic pain patients? 
3.  Does case management reduce the prevalence of opioid misuse in chronic pain patients? 
4.  Does management by pain specialists reduce the prevalence of opioid misuse in chronic pain 
patients compared to management by primary care providers? 
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5.  Do prescription monitoring programs lead to a reduction in the prevalence of opioid misuse 
among chronic pain patients? 
 
Inclusion and Exclusion Criteria 
Using the key questions, I constructed inclusion and exclusion criteria for the studies to 
be included in this review.  Only English language articles were included.  Both interventional 
and observational study designs were eligible for inclusion.  Articles from any year were eligible 
for inclusion, up until the date the search was performed (May 8, 2007).  Editorials and reviews 
were excluded, as well as case reports and studies enrolling fewer than 10 patients.   
Included studies were limited to those that evaluated misuse of opioids in patients with 
chronic pain.  The patient population included all patients with chronic pain (pain lasting longer 
than three months).  No subtypes of chronic pain were excluded to improve the generalizability 
of the results.  Studies were included whether or not they incorporated the use of a control group.  
Specific populations that were excluded included patients with acute pain (lasting shorter than 
three months), and patients enrolled in substance abuse programs.  Articles were excluded from 
the abstract review if the abstract made no mention of the intervention in question (treatment 
agreements, urine drug testing, case management, pain specialists or prescription monitoring 
programs). Although the main outcome was the prevalence of opioid misuse, abstracts that made 
no mention of misuse were still included for full text review, in the event that misuse was 
measured but not mentioned in the abstract.  For case management, any abstract that made 
mention of a multi-disciplinary approach was included for full review, on the chance that it may 
include case management as part of the multi-disciplinary approach. 
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To limit the reviewed articles to those that evaluated the effectiveness of interventions in 
reducing the prevalence of opioid abuse in chronic non-cancer pain patients, studies were 
excluded after full text review if 1) they did not evaluate the proposed intervention, 2) they were 
cross-sectional studies, 3) they did not measure opioid misuse, 4) they had no control group and 
did not have any baseline data on opioid misuse, or 5) they did not assess the role of the specified 
intervention independently of other interventions. 
 
Literature Search and Retrieval Process 
Databases and Search Terms.  MEDLINE was searched by one reviewer for relevant 
articles using the following search strategy.  The search strategy for each of the key questions 
was developed with assistance from a Health Sciences Librarian.  Each of the key questions 
included the term ―(chronic disease OR chronic) AND pain AND ("Analgesics, Opioid"[MeSH] 
OR Opioids)‖ for the first search term.  This limited the available studies to those that deal with 
opioid use in patients with chronic pain.  Each key question had a different second search term, 
connected to the first search term by the Boolean operator ―AND‖.  For the question of urine 
drug testing, the second search term used was ―(Substance Abuse Detection OR urine toxicology 
OR ―drug testing‖)‖.  For the question of treatment agreements, ―(contracts OR "treatment 
agreement" OR "medication agreement" OR agreement[ti])‖ was used.  For the question of case 
management, ―(case management OR patient care management)‖ was used, because these terms 
were felt to cover all the literature pertaining to case management.  For the question about pain 
clinics vs. primary care practice, ―(pain clinic OR pain clinics OR spine clinic OR orthopedics 
OR specialty)‖ was used for the second search term.  Finally, for the question about prescription 
drug monitoring programs, the second search term ―(prescription OR controlled substance) AND 
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(monitoring OR reporting) AND (system OR program OR programs)‖ was used.  The search was 
not limited to English language articles only, but non-English articles were excluded after 
abstract review.  This permitted the assessment of possible language bias, since trials with more 
positive results
 
are more likely to be published in English.
44
 No date parameters were set, but the 
earliest article in the search results was published in 1976.  Also, a hand search was performed 
using reviews and studies found in the initial searches to locate other articles that may answer the 
study questions.  Experts in the field were consulted to locate further articles not found in the 
MEDLINE search or the hand search. 
 
Article Selection and Review.  One reviewer evaluated abstracts for inclusion or 
exclusion. If the articles were not excluded based on abstract review, then the full article was 
reviewed.  Studies identified by expert consultation and hand review were also included for full-
text review.  After full text review, if the article was not found to meet the inclusion criteria, the 
article was excluded.  Relevant information from all articles included in the full-text review was 
entered into evidence tables: included studies were entered into Table 1, and excluded studies 
were entered into Table 2. 
 
Evaluation of Quality and Strength of Evidence 
The articles were assessed for quality scope and relevance.  Criteria established by 
Agency for Healthcare Research and Quality
45
 were used to grade the strength of each study as 
good, fair or poor.  I graded the quality of each article by assessing the degree to which chance 
and certain biases were minimized through the study design.  To minimize the role of chance, 
studies would receive a better score if the study population were large.  For selection bias, the 
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study received a good score if initial comparability of groups was good (if a control group was 
present), and intention-to-treat analyses were performed.  For measurement bias, the study was 
rated well if the measurements of intervention and outcome were equal, valid and reliable.  For 
confounding bias, the study was rated well if selection bias was minimal and the results of the 
analysis were controlled for potential confounding variables.  Because each article was rated by 
only one reviewer using a non-validated rating scale, the quality ratings of each study should be 




Flow of Studies through the Review Process 
A total of 332 articles were identified for five different questions (excluding duplicates 
identified for multiple study questions); 18 regarding treatment agreements, 39 regarding urine 
drug testing, 156 regarding case management, 166 regarding pain specialists, and 10 regarding 
prescription reporting systems.  See Figure 1 for a flow diagram of studies through the 
systematic review process.  Thirty-nine of these articles were not in English, and most of the 
non-English articles were identified in the case management and pain specialist searches.  Since 
only a small proportion of the total articles were not in English (10%), I estimated that language 
bias would not be a significant issue.   
A large proportion of identified abstracts were reviews or editorials (166 articles), and 
these were excluded before full-text review (some of these were reviewed later during the hand 
search).  Also, 26 case reports were excluded.  Of the remaining 158 studies, 119 either made no 
mention of the study question asked by the review because they dealt with a different question 
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altogether, or dealt with the correct study question but in a different population (patients with 
acute pain, or patients on methadone in a substance abuse rehabilitation program).  A reference 
list search of pertinent reviews and studies identified no further articles for full-text review.  
Expert consultation revealed one not yet published article for full text review evaluating the 
effect of prescription monitoring programs. 
A total of 22 articles, excluding duplicates, were reviewed in full (3 regarding treatment 
agreements, 10 regarding urine drug testing, 2 regarding case management, 11 regarding pain 
specialists, and 2 regarding reporting systems).  The details of the included studies can be found 
in Table 1,
36,46-51
 whereas details about excluded studies can be found in Table 2.
17,27,28,46,49,52-65
  
Nineteen total studies were excluded from the final analysis, from one or more categories (a few 
of which were included in a different category).  For treatment agreements, reasons for exclusion 
were: 1) the study did not measure misuse (n=1) or 2) the study did not assess the role of 
treatment agreements independently (n=1).  For urine drug testing, reasons for exclusion were: 1) 
no follow-up (n=4), or 2) no control group or baseline misuse data to assess the effectiveness of 
urine drug screening (n=4).  Those studies that did assess urine drug screening over time reported 
the incidence of opioid misuse over a block of time, rather than the prevalence at the beginning 
vs. the prevalence at the end (a pre-post design
66
), which would be helpful to determine whether 
urine drug screening is actually effective in reducing the prevalence of opioid misuse.  For case 
management, reasons for exclusion were: 1) the study did not assess the role of case management 
(n=2).  For pain specialists, reasons for exclusion were: 1) misuse was not measured as an 
outcome (n=5), 2) no follow-up (n=1), 3) pain specialists were not evaluated independently 
(n=1), or 4) no control group or baseline data were available to evaluate the effectiveness of the 
intervention in reducing the prevalence of opioid misuse (n=3).  Finally, for prescription 
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monitoring programs, reasons for exclusion were: 1) the study did not assess the role of 
prescription monitoring programs (n=1). 
In the end, five studies were included in the systematic review: one uncontrolled study 
evaluating treatment agreements, two prospective historically-controlled studies evaluating the 
effectiveness of urine drug testing in reducing opioid misuse, one uncontrolled study evaluating 
pain specialists, and one ecological study evaluating the effect of prescription drug monitoring 
programs in twenty states.  No studies were included for the effectiveness of case management in 
reducing the prevalence of opioid misuse. 
 
Treatment Agreements 
One uncontrolled study was identified
46
 that evaluated the incidence of opioid misuse in 
chronic pain patients who signed treatment agreements with their providers.  Hariharan et al. 
recorded treatment agreement outcomes over five years in 330 patients with chronic pain who 
were started on long-term opioids.  Over the five years, only 17% (n=54) of contracts were 
cancelled by the physician.  Broken up by subgroup, 8% (n=27) of contracts were cancelled due 
to positive urine toxicology screening, 4% (n=14) due to prescription drug abuse, 1% (n=4) due 
to contract rules violations, and 3% (n=9) due to administrative reasons such as transfer of care 
to a specialist.  Only 42% of patients had any urine drug screening performed; of this sample 
38% tested positive for illicit drugs.  Urine drug screening was more likely to be used in patients 
who were male, young, or who were taking long-acting or combination (short- and long-acting 
opioid used in combination) therapy.  Urine drug screening was less likely to be used in patients 
with degenerative joint disease.  The study does report that opioid misuse was significantly 
associated with male gender and combination therapy. 
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This study’s quality was rated as fair.  The lack of a control group makes any effect of the 
treatment agreement difficult to quantify.  Also, the inconsistent use of urine drug screening may 
bias the associations found in the study.  For example, opioid misuse was associated with male 
gender and combination therapy, but urine drug screening was performed more often in these 
groups.  This leads to a measurement bias because the use of testing is not equal in different 
groups.  Still, the investigators should not be faulted for this measurement bias, because the use 
of urine drug screening was not controlled by the investigators (it was an outcome in and of 
itself).  From these data, one can now predict the likelihood of a physician to use urine drug 
screening in the context of a treatment agreement. 
 
Urine Drug Testing 
Two articles were identified
47,49
 that evaluated the effectiveness of urine drug testing in 
reducing the prevalence of opioid misuse among chronic pain patients and compared the results 
to controls.  Laxmaiah Manchikanti is the primary author of both articles.  The patient 
demographics are identical in both studies, indicating that the two articles appear to be different 
reports from the same data.  The patient population included 500 consecutive chronic pain 
patients on opioids.  One of the articles reports the effectiveness of adherence monitoring 
(including urine drug testing) in reducing controlled substance abuse
47
 compared to historical 
controls.
48
 The other focuses on the reduction of illicit drug use,
49
 compared to a different 
historical control.
50
 Both of these outcomes—controlled substance abuse and illicit drug use—
are included in the definition of opioid misuse
17
 used by this review. 
The former article
47
 reports a 50% reduction in opioid abuse with the institution of 
adherence monitoring, which includes treatment agreements, periodic urine drug testing and pill 
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counts. This corresponds to an absolute decrease in opioid abuse of 8.8% (prevalence of 17.8% 
in the control and 9% in the intervention).  The control group consisted of 500 patients from a 
previous study
48
 in 2003 which did not incorporate the use of urine drug screening or pill counts.  
The investigators found that, out of the 9% who abused opioids, 5% did so by doctor shopping 
(i.e. requesting prescriptions from multiple providers), and 4% did so by illegal acquisition 
through drug trafficking.  Even though the intervention in this trial included treatment 
agreements as well as urine drug testing, the referenced control group
48
 included the use of 
treatment agreements.  Therefore, any effect of the intervention should be attributed primarily to 
urine drug testing and pill counts. 
The latter study
49
 reports that adherence monitoring reduces the prevalence of illicit drug 
use from 22% in the historical control to 16% in the intervention group.  The historical control 
consists of 400 consecutive patients from a previous study
50
 in 2005.  Of note, participants in the 
control group also received urine drug screening.  Out of the 16% illicit drug users, 11% abuse 
marijuana, 5% abused cocaine, and 2% abused methamphetamine or amphetamines.  In 
subgroup analysis by insurance status, they also report a statistically significant decrease in illicit 
drug use among the Medicaid population (22% compared to 39% in the control), most 
prominently in the form of decreased marijuana use (16% compared to 34% in the control). 
Using the AHRQ guidelines,
45
 I rated the quality of the prescription drug abuse study as 
fair, and the illicit drug use study as poor. Patient comparability is good in both studies, except in 
the distribution of different types of insurance in the illicit drug use study.  Also, data for 
experimental and control groups are taken from different studies, which may introduce some bias.  
In both cases, the investigators report that the study design is prospective, but the length of the 
study is unspecified.  If the data were collected during only one patient visit, this would call into 
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question the effectiveness of the intervention.  Also, the frequency of random urine drug screens 
is unspecified, so the point at which urine drug testing data are obtained is unclear. 
In the study that examines the effect of urine drug testing on illicit drug use, the 
investigators compare the effects of the intervention
49
 to a control group
50
 in which patients also 
gave consent to the use of random drug monitoring through urine drug screening.  If the 
intervention were present to the same degree in both the experimental group and the control 
group, one would not expect to see much of a difference in outcomes between the two groups.  
Regardless, any reduction in the prevalence of illicit drug use in the experimental arm should not 
be attributed to the intervention, but rather to chance or to some other difference between the two 
groups. 
For this reason, the illicit drug use study’s quality was rated as poor.  Since urine drug 
testing was performed in both groups, determining the cause of the decrease in prevalence is 
difficult.  Part of this difference could be explained by a difference in representation of the 
subgroups.  The experimental group contained a higher proportion of Medicare recipients (with a 
lower prevalence of illicit drug use) than did the control group.  Also, the experimental group 
contained a lower proportion of Medicaid recipients (with a higher prevalence of illicit drug use) 
than did the control group.  Both of these situations would lead to an underestimation of the total 
prevalence of illicit drug use in the experimental group.   
 
Pain Specialists 
One uncontrolled study was identified
51
 that evaluated the effectiveness of a specialist 
program over time.  Currie et al. measured the effectiveness of a ten week integrated pain 
management program for recovering substance abusers.  The program consisted mostly of 
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cognitive-behavioral therapy with elements of substance abuse education and relapse prevention.  
Two professionals facilitated the discussions: an occupational therapist and a family physician, 
both experienced in chronic pain and addiction medicine.  Patients were referred to the program 
if they had a chronic pain condition and a concurrent diagnosis of substance abuse or substance 
dependence.  The definition of substance dependence accepted by the investigators included 
many behaviors classified under opioid misuse: e.g. consuming more medication than prescribed, 
combining opioids with other drugs for pain relief, obtaining prescriptions from multiple 
providers, or buying opioids from others.   
At baseline, 91% of participants had a diagnosis of substance dependence and 9% had a 
diagnosis of substance abuse.  Behaviors were assessed at baseline using the Addiction Severity 
Index and supplemental questions derived from the Diagnostic and Statistical Manual-IV.  Over 
a 12 month follow-up, patients showed improvements in many Addiction Severity Indices, 
including medical, psychological, and employment indices.  Some of these indices included 
―days with medical problems‖ (23.8 out of 30 days at baseline, compared to 19.2 out of 30 days 
at 12 months), ―days with psychological problems‖ (17.4 out of 30 days at baseline, compared to 
12.9 out of 30 days at 12 months), and ―concern about employment problems (0-4)‖ (1.7 out of 4 
at baseline, compared to 0.9 out of 4 at 12 months).  Opioid use decreased over the course of 
follow-up (68% at pre-treatment, 59% at post-treatment, 52% at 3 months, and 50% at 12 
months). 
This study was rated as fair.  The absence of a control group allows for confounding bias 
when analyzing the results.  However, because participants were referred to this program 
because they could not solve their problems independently, one could assume that a control 
group would show no improvement over the 12 month study period (or perhaps a decline in the 
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measured indices).  Selection bias is a concern, because the study had a large drop-out rate (34%) 
which consisted mostly of people who developed problems with the treatment program.  This 
bias was minimized by obtaining follow-up data for a proportional number of drop-outs from the 
program.  The major limitation of this study that elicited a rating of ―fair‖ was that follow-up 
data concerning patient addiction measures relied on self-report rather than objective measures of 
misuse. 
 
Prescription Drug Monitoring Programs 
One article was identified
36
 that dealt with the effectiveness of prescription drug 
monitoring programs (PDMPs) in reducing the abuse of schedule II drugs, including opioids.  
This manuscript, by Ronald Simeone and Lynn Holland, was not yet published at the time of this 
review; the article was obtained with the help and permission of Kay Sanford, MSPH, in the 
Injury and Violence Prevention Branch of the North Carolina Department of Health and Human 
Services, Division of Public Health.  The study uses an ecological study design comparing states 
with a PDMP to states without a PDMP. 
At the time of the study, prescription drug monitoring programs were in place in twenty 
states.  Data from states without prescription monitoring programs were used as a control group 
to compare six year trends.  The investigators reported the relationship between PDMPs and 
prescription drug abuse using both an indirect and a direct channel.  The indirect method 
involved comparing over six years (1997-2003) the supply of Schedule II drugs in states with 
PDMPs to states without PDMPs.  They argue that decreasing the supply of prescription drugs 
reduces the probability of abuse.  Using data from Automation of Reports and Consolidated 
Orders System (ARCOS), they found that, although supply of most Schedule II drugs had 
 28 
increased over the six year interval, the rates of increase were lower in states with PDMPs than 
in states without a PDMP for all pain relievers except hydromorphone, which showed 
comparable rates of increase.  Also, states with proactive PDMPs have a slower rate of increase 
in supply than states with reactive PDMPs. The investigators go on to develop a multilevel 
individual response model which is used to support their hypothesis that prescription drug supply 
is linked with probability of prescription drug abuse, and consequently probability of admission 
to a drug treatment program. 
The direct method involved using the data from all patient admissions into state-licensed 
drug treatment programs.  Patient admissions data represent only those people seeking treatment 
for drug abuse, and therefore only catches a small minority of total people with drug abuse 
problems.  This data does not show any significant differences between states with PDMPs and 
states without PDMPs.   
The quality of this study was rated as good.  The use of a control group (states without 
PDMPs) as well as trend analysis reduces the role of bias in the study design.  This study clearly 
shows that the existence of a PDMP is associated with a slower rate of increase in supply of 
prescription drug supply, specifically Schedule II drugs.  By using the multilevel individual 
response model, they further support their hypothesis that drug supply is closely linked to 
probability of abuse.  The main drawback of this study design is that no data concerning illicit 
drug use are available, precisely because illicit drugs are illegal in all situations and their supply 
is not well known.  Thus, no information is available for the patients who misuse their opioid 
prescription by taking illicit drugs concurrently.  Also, it is difficult to determine to what extent 




In summary, evidence is scarce for the benefits of treatment agreements, urine drug 
testing, case management, pain specialists and prescription drug monitoring programs in the 
reduction of the prevalence of opioid misuse in chronic pain patients.  Different investigators 
have evaluated the effectiveness of interventions over time, but many of these investigations lack 
both a control group and baseline data regarding the prevalence of opioid misuse.  
Based on the limited data available, tentative conclusions can be made regarding four of 
the five interventions evaluated by this review.  Treatment agreements are associated with a 
prevalence of opioid misuse of 13% after five years (assuming that the prevalence of opioid 
misuse is 0% at baseline because patients are beginning opioid therapy).
46
  Urine drug testing 
decreases the prevalence of prescription drug abuse by 8.8%
47





 but the quality of the data is questionable.  Specialized pain 
treatment programs reduce reliance on opioid medications as well as indices of addiction.
51
  
However, the studied specialist treatment program may be quite different from a typical pain 
specialist clinic. Unpublished research concerning prescription drug monitoring programs has 
shown that the presence of a PDMP clearly slows the rate of increase in supply of Schedule II 
drugs, including opioids.
36
  They also show that states with proactive PDMPs have slower rates 
of increase in supply than states with reactive PDMPs.  By using statistical modeling, they argue 
that an increase in supply leads to an increase in the probability of abuse.
36
   
The relationship between supply and abuse is strongly supported by recent work 
comparing opioid analgesic sales to drug poisoning mortality by state.
67
 Significant positive 
correlations were found between drug poisoning mortality and statewide sales of methadone, 
oxycodone, and hydromorphone individually.  A scatterplot from this research demonstrated a 
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linear relationship between total opioid sales and mortality from drug poisoning (Figure 2), 
reinforcing the conclusion that an increase in opioid supply leads to an increase in the likelihood 
of abuse.  This conclusion is provocative because—although preliminary—it links physicians 
prescribing behaviors to deterioration, not amelioration, of an important public health problem. 
This review contains notable strengths.  First, the search strategies were developed in 
consultation with a health sciences librarian as well as experts in the field.  The breadth of the 
search strategies was confirmed when different articles recommended by experts in the field 
were present in the search.  Second, this review addresses a number of different strategies for the 
reduction of opioid misuse.  Third, the inclusion of a flow diagram allows the reader to see why 
studies were excluded, whether because the articles were reviews, studies that did not answer the 
review question, or articles that were not published in the English language. 
This review also has some limitations.  The most notable limitation is that abstracts and 
full-text articles were reviewed by only one reviewer.  The involvement of two different 
reviewers would decrease the role of individual bias in selecting articles.  If two reviewers had 
judged the abstracts, ideally a third person would classify any articles for which the first two 
reviewers disagreed.  The role of individual selection bias was reduced by using strict 
predetermined inclusion and exclusion criteria.  The inclusion of the search strategies as well as a 
detailed flow diagram of included and excluded studies allows the reader to appraise the quality 
of the review for him or herself.  Another limitation is that the quality of each included article 
was similarly rated by only one reviewer.  This, again, can introduce personal bias.  However, 
important study characteristics were detailed to allow the reader to make his or her own 
conclusions about the quality of the studies. 
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As far as I know, this is the first systematic review of its kind that deals specifically with 
the reduction of opioid misuse among chronic pain patients.  A narrative review by Kahan et al.
18
 
has dealt with the question of opioid misuse, and provided helpful information about the 
interpretation of urine drug testing, as well as a recommendation to routinely use treatment 
agreements, to titrate opioid dosing cautiously, and to watch for signs of misuse.  The narrative 
review also confirms that most recommendations regarding identification and management of 
opioid misuse are based on expert recommendation.   
This systematic review contributes to the body of current literature in a number of ways.  
First, the flow diagram (Figure 1) shows us the distribution of literature surrounding these 
topics.  Out of the many articles identified, only five dealt specifically with misuse using a 
control group or having a pre-post study design.  This confirms the lack of available evidence 
concerning the effectiveness of different interventions to reduce the prevalence opioid misuse 
among chronic non-cancer pain patients.  Also, the two articles dealing with urine drug testing 
are difficult to use in making any conclusions about urine drug testing, due to methodological 
flaws and omitted information. 
This review has identified new evidence supporting the role of prescription drug 
monitoring programs.  This evidence can be used to recommend the institution of PDMPs in 
states that do not yet have them.  Also, the evidence concerning the difference between proactive 
and reactive PDMPs may encourage states with reactive PDMPs to make the necessary changes 
to take a more proactive stance to reduce the prevalence of opioid misuse.  This evidence can 
also be used to encourage clinicians in states with a reactive PDMP: although the system itself 
does not proactively notify the clinicians about problem patients, the clinician can use the system 
in a more proactive way.  By contacting the PDMP for every chronic pain patient, the clinician 
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can in effect make the reactive PDMP a proactive one, and one would hope that this would lead 
to less probability of opioid misuse through reductions in the supply of these drugs. 
The implications of this review for future research are several.  First of all, more research 
must be done to quantify the effects of these strategies in reducing the prevalence of opioid 
misuse.   Also, during the process of this review, I came upon well-designed studies that 
evaluated the effectiveness of different interventions, but did not quantify opioid misuse.  For 
example, Becker et al.
60
 performed a randomized trial comparing pain management in a multi-
disciplinary pain center to that in a general care practice, but did not include opioid misuse as an 
outcome.  As opioid misuse becomes a more prevalent issue in our society, researchers should 
make reasonable efforts to include misuse as an outcome in comparative trials.  Also, efforts 
should be made when possible to either include a control group or to quantify baseline opioid 
misuse.  These methods would add valuable information regarding the effectiveness of different 
interventions to reduce the prevalence of opioid misuse. 
The effectiveness of many of these strategies in reducing the prevalence of opioid misuse 
is still unknown.  However, many of these strategies serve other purposes besides preventing 
opioid misuse.  Treatment agreements allow the clinician to protect him or herself by terminating 
the relationship if the patient demonstrates clear opioid misuse.  Although the utility of urine 
drug testing as an accountability tool to reduce the prevalence of opioid misuse is not well 
appreciated, it is still useful as a measurement tool.  In the same way, primary care physicians 
refer their patients to pain specialists for reasons other than an opioid misuse problem.  While the 
utility of these strategies in reducing the prevalence of opioid misuse is unknown, they can still 





What can we infer? 
The existing body of literature is limited in addressing the study questions as they were 
asked by this review.  To augment our understanding of the issues involved with these 
interventions, we can infer conclusions about the effectiveness of different strategies using other 
studies and related work.  Until research is performed that answers these questions directly, the 
works mentioned below, as well as others, will provide the best available information. 
 
Treatment Agreements.  Although no studies were located that evaluated the 
effectiveness of treatment agreements using a control group, studies without control groups can 
be compared to data obtained in other studies to gain some understanding about the utility and 
success of treatment agreements. In the Hariharan study,
46
 if we remove those patients whose 
agreements were cancelled due to administrative reasons, opioid misuse was detected in 13% of 
patients over five years.  This percentage falls within the 3 to 19% range of opioid misuse among 
patients at tertiary pain clinics reported earlier.
18
  These percentages were likely calculated from 
practices that included treatment agreements as well, making a conclusion regarding the 
effectiveness of opioid contracts difficult.  A noteworthy limitation of the study is that less than 
45% of patients received urine toxicology screening, so the total prevalence of opioid misuse 
using this important tool is probably underestimated.  This brings up an important observation: 
lacking any specific urine drug testing protocol, urine drug testing is likely to be underutilized as 
a diagnostic tool.   
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The study does report that opioid misuse was significantly associated with male gender 
and combination therapy (although urine drug screening was performed more frequently in these 
groups as well).  Thus, although we do not know the overall effectiveness of treatment 
agreements, we do have some evidence that treatment agreements are more likely to be 
successful in female patients as well as those patients who are managed on only one opioid 
medication (although these observations should be confirmed by research with tightly controlled 
measurement strategies).   
This review did not identify any studies in which treatment agreements were instituted 
after opioid therapy had already begun.  Studies could evaluate this by estimating the prevalence 
of opioid misuse before treatment agreements are instituted, and measuring again after treatment 
agreements are instituted.  This type of study design could provide clear data to show whether 
treatment agreements have a noticeable effect in decreasing the prevalence of opioid misuse 
among chronic pain patients.   
 
Urine Drug Testing. While the effectiveness of urine drug testing has not been well 
studied in the chronic pain population, it may be possible to make some inferences from the 
literature surrounding random drug testing in other environments.   
Urine drug testing in the public school system may provide some interesting inferential 
hypotheses.  While many differences exist between the adolescent population and the chronic 
pain population, random urine drug testing should have at least one similar effect in both groups: 
the reduction of illicit drug use.  Yamaguchi et al.
68
 compared adolescent self-reported illicit 
drug use to the presence of drug testing in the school.  Between the years 1998 to 2001, 18.14% 
of schools reported using drug testing of any kind.  No association was found between the 
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presence of a drug testing program in the school and the prevalence of self-reported illicit drug 
use.  The lack of association persisted after controlling for various demographic factors.  If the 
chronic pain population responds to urine drug testing in a similar way, we might expect that 
urine drug testing would not be an effective method to reduce the prevalence of opioid misuse. 
However, it is important to note that the drug testing programs in most schools at the time 
of this study were not actually random.  Of the total schools using drug testing (18.14% of total 
schools), 78% (14.15% of total schools) of schools reported that they only tested due to cause or 
suspicion.
68
 If testing due to cause or suspicion is less effective on a population scale than true 
random testing, this would bias the results of the study toward the null. Therefore, we may 
expect that urine drug testing, when applied based on suspicion rather than randomly throughout 
the chronic pain population, may not have any better effect than that of drug testing in schools.  
This conclusion has important applications for many healthcare professionals treating chronic 




The use of urine drug testing in the workplace may also offer interesting information.  
While workplace drug testing is unpopular in the general public and denounced by the American 
Civil Liberties Union,
69
 a recent study of workplace drug testing in the Finnish Defence Forces
70
 
may provide evidence for its effectiveness.  In this setting, workplace drug testing was part of an 
overall anti-drug strategy, which included public proclamation of zero-tolerance to illicit drugs 
and emphasis on the importance of the healthy drug-free way of life.  While they acknowledge 
that the publicity of this program may have led to some selection bias in those who applied for 
positions, they report an amazingly low detection of illicit drug use (only one positive test in 
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over 2000 samples in four years).  They conclude that the anti-drug strategy must be at least 
partly responsible for findings.   
It is difficult to say whether evidence concerning urine drug testing in the school system 
or in the workplace can be used to infer the effectiveness of testing in chronic pain patients.  
Many differing factors between the populations may make generalizations difficult.  For 
example, one important difference in the chronic pain population is that the physician is both the 
supplier of opioids as well as the enforcer of proper adherence practices.  In order to truly assess 
the effectiveness of urine drug testing in the reduction of opioid misuse, it will be necessary to 
conduct well-designed studies in chronic pain populations, using a standard protocol for the use 
of random urine drug testing.  Future research concerning the effectiveness of urine drug testing 
should take care to carefully define the methods by which urine drug testing is implemented, as 
this may have a significant effect on the effectiveness of urine drug testing.   
This research may be difficult in the case of urine drug testing, because the intervention is 
also the method by which outcomes are measured.  A study could be designed in which urine 
drug testing is performed on all patients, but the results would not be available to the physicians 
of patients in the control group.  This distinction would have to be clearly communicated to the 
patients in each group in order to accurately measure the psychological impact of urine drug 
testing on patients’ decisions.  One would hypothesize, then, that opioid misuse would be less 
prevalent in the group in which urine drug testing results are available to the physician.  If this 
were true, we could show that urine drug testing is not only effective as a measurement tool, but 
also as an intervention to reduce the incidence of opioid misuse in chronic pain patients. 
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Case Management. No evidence was found of the effectiveness of case management in 
the setting of chronic pain treatment.  However, case management has been studied in the setting 
of substance abuse treatment programs.  Case management has been shown to be effective in 
increasing enrollment in substance abuse treatment programs,
71
 and in retaining the patients,
72
 
but does case management help to reduce the prevalence of substance abuse? 
McLellan et al.
73
 report the benefits of case management in the management of substance 
abusers in Philadelphia from 1998-2001.  During this time, the five largest detoxification 
programs in the city of Philadelphia identified ―Multiple-Detoxification Only‖ patients (i.e. 
patients admitted to any detoxification unit three or more times in the past twelve months) and 
assigned clinical case managers to these patients.  890 patients received clinical case 
management over the course of the three year intervention.  The case managers provided many 
different services, including assessment, negotiating a service plan, problem solving, contacting 
agencies and providing transportation. Out of a sample of the first 100 patients who received 
case management in the third year of the intervention, the researchers found a marked reduction 
in the number of patients who received detoxification-only admissions (67% to 30%), and 
increases in the proportion of patients utilizing rehabilitation services (30% to 70%).  This 
implies that the case managers were able to help patients use the healthcare system effectively by 
utilizing continuity care (rehabilitation) rather than emergency care (admission to a 
detoxification unit).   
One can imagine that these benefits would translate into improved outcomes for chronic 
pain patients: decreased emergency department utilization, improved use of the chronic pain 
visit, with decreases in opioid misuse due to improved adherence to the prescribed regimen.  
However, this inference should be made cautiously for several reasons.  First, the intervention in 
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Philadelphia was uncontrolled, so the exact effect of case management is difficult to determine.  
Also, it is unclear whether the benefits of case management will be the same in chronic pain 
patients as they are in substance abuse patients.  There may be some overlap in these 
populations, as some patients with uncontrolled pain may resort to self-medication and 
eventually become substance abusers and develop substance dependence.   
Even if case management is found to be effective in reducing the prevalence of opioid 
misuse among chronic pain patients, it will be important to discern the optimal level of 
involvement of the case manager.  Recent research in the opioid dependence literature has shown 
that the efficacy of thrice-weekly medication dispensing and extended weekly counseling 
sessions did not differ significantly from that of once-weekly dispensing and brief weekly 
counseling sessions.
74
 If the services provided by case managers are found to be beneficial for 
chronic pain patients, more contact may not improve outcomes to a greater extent. 
 
Pain Specialists.  Although finding a controlled evaluation of the effectiveness of pain 
specialists is difficult, uncontrolled studies can provide important information.  To the extent that 
patients are recruited from practices in which they had received the maximum benefit possible 
from standard care, patients’ baseline data could substitute as a surrogate control group for 
comparison.  In other words, if a patient had been stable in pain control and functional status for 
many years in a primary care setting, we could assume that the patient had received his or her 
maximum benefit from customary care.  If this patient, who had benefited maximally from 
standard care, showed improvement in response to the intervention, one could infer that the 
improvement is a result of the intervention, in much the same way that one could conclude this 
using a comparison to a control group.  However, this type of observation requires some baseline 
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observation regarding prevalence of opioid misuse, which is difficult because misuse is 
measured over time.  Three such studies were excluded from this review based on the fact that 
they lacked a control group and could not obtain baseline data, and they deserve some mention 
here.   
Chelminski et al.
53
 performed a 3-month study evaluating the effectiveness of a 
multidisciplinary disease management program in many patient outcomes, including misuse of 
opioids (using the definition of misuse cited by this review).  Physicians were encouraged to 
refer patients if they were having difficulty managing the patient’s pain, or if the physician 
suspected opioid misuse.  In this situation, as above, we can assume that the patient has received 
the maximum possible benefit from standard care.  Therefore, improvements at three months 
over baseline can probably be attributed to the intervention.  The investigators did find 
improvements in pain, disability and depression scores.  However, because the determination of 
opioid misuse requires observation over time, no baseline status of opioid misuse was available, 
making inferences regarding the effectiveness of the program in reducing misuse difficult.  Over 
the course of the study, 32% of patients committed some form of serious opioid misuse. 
Chabal et al.
54
 looked at 403 chronic pain patients in a pain clinic at the Seattle VA 
Medical Center, 76 of which were on chronic opioid therapy.  They defined opioid abuse as: (1) 
an overwhelming focus on opioid issues by the patient lasting beyond the third visit, (2) pattern 
of early refills or escalating drug use, (3) multiple telephone calls or visits to the clinic asking for 
refills or creating a disturbance, (4) pattern of reporting lost, spilled or stolen medications, or (5) 
supplemental sources of opioids from other providers.  Using these criteria, they found that 34% 
(26/76) of chronic opioid users in this study met one or more criteria, and 28% (21 patients) met 
three or more criteria.  In a one year follow-up of these 21 patients, 3 remained in the VA system 
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on stable doses of opioids, 4 were being prescribed opioids by psychiatrists not at the pain clinic, 
and 14 were no longer treated at the VA system (9 of which had completed drug treatment or had 
legal difficulties over opioid use).   
Mahowald et al.
64
 evaluated 230 orthopedic spine clinic patients over the course of 3 
years for improvement in certain outcomes: improvement in pain, dosage escalations, side 
effects, and incidence of abuse.  They found the frequency of opioid abuse behaviors in long-
term opioid users (greater than 3 months) to be 5%.  However, opioid abuse was diagnosed by 
interview only, and the use of urine drug testing was not mentioned as a measurement tool.  
Given this fact and comparing to estimations in other studies, their estimate of opioid misuse 
may be artificially low. 
 
New Directions in the Prevention of Opioid Misuse 
While the existing body of literature surrounding the topic of opioid misuse is limited, 
new work is being published rapidly to address this growing problem.  Multiple screening tools 
are being developed to assist the clinician in the assessment of opioid misuse risk.  The Pain 
Medication Questionnaire has shown predictive value for substance abuse, psychopathology, and 
physical/life-functioning.
75
 The Opioid Risk Tool has demonstrated high sensitivity and 
specificity for determining risk of opioid related, aberrant behaviors.
76
 The Addiction Behaviors 
Checklist is a viable assessment tool to increase a clinician’s confidence in determination of 
inappropriate opioid use.
77
 These tools may help the clinician to target certain individuals for 
higher levels of adherence monitoring.  It is important to remember, however, that misuse-
monitoring strategies such as urine drug testing may be most effective when administered 
randomly rather than specifically targeted towards high-risk individuals. 
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Opioid misuse is a public health problem, affecting the chronic pain population as well as 
drug addicts.  As such, opioid misuse requires a public health answer.  The primary care 
clinicians in contact with the patient cannot be expected to bear the entire burden of managing 
this problem.  The potential role of case management has already been mentioned, as has the role 
of the state, by gathering data and making it available through prescription drug monitoring 





Psychiatrists have also been encouraged to take a more active role in pain management.
80
 
Medical school administrations have an important part to play in addressing the problem 
of opioid misuse.  A study of general practitioners in Sweden
81
 has shown that physicians 
experience internal dilemmas when prescribing opioids, concerning the appropriateness of the 
drug and the concern about abuse and addiction.  These dilemmas only rarely led to a denial of 
an opioid prescription for the patient.  The researchers suggest that physicians need more training 
in saying no to patients, or perhaps better education regarding the proper indications for opioids.   
This hypothesis is supported by other research that surveyed a medical school class as 
freshmen and again as seniors.
82
 They found that seniors scored lower on opiophobia scales than 
they had as freshmen (meaning that they became less reluctant to prescribe opioids, expressed 
less fear of patient addiction, and expressed less fear of investigation by a Drug Regulatory 
Agency).  However, more than half of the seniors believed patient addiction risks to be 
substantial, and more than one third expressed fear about investigation.  Also, senior students 
had a more negative attitude towards patients’ psychological problems and a more pessimistic 
outlook on relieving chronic pain.  Medical schools have a unique opportunity to engage this 
issue by devoting time to the education of medical students regarding these issues. 
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Other public health strategies have targeted inner city drug use.  The death rate in 
Baltimore due to drug intoxication hit a 10 year low in 2006, due to efforts of the city to make 
drug treatment readily available, and to provide naloxone (an opioid antagonist) to addicts to 
reverse the effects of opioid overdose themselves.
83
 Another group in New York City has done 
focus group research to elucidate why resistance to using naloxone exists.
84
 Efforts to target all 
users of opioids—whether chronic pain patients or heroin addicts—will be necessary to reduce 
the prevalence of opioid misuse and deaths that occur as a result.  These new techniques, as well 
as those currently recommended by different guidelines, require further study in order to provide 




1. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA.  The epidemiology of 
chronic pain in the community.  The Lancet.  Oct 1999; 354: 1248-1252. 
2. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in 
Europe: prevalence, impact on daily life, and treatment.  Eur J Pain. 2006 May;10(4):287-333. 
3. Institute for Clinical Systems Improvement (ICSI).  Assessment and management of 
chronic pain.  Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Mar. 
4. Office of Applied Studies. (2005). Results from the 2004 National Survey on Drug Use 
and Health: National findings (DHHS Publication No. SMA 05-4062, NSDUH Series H-28). 
Rockville, MD: Substance Abuse and Mental Health Services Administration. 
5. Veterans Health Administration, Department of Defense.  VA/DoD clinical practice 
guideline for the management of opioid therapy for chronic pain.  Washington (DC): Veterans 
Health Administration, Department of Defense; 2003 Mar. 
6. North Carolina Medical Board.  Policy for the Use of Controlled Substances for the 
Treatment of Pain.  Available at http://www.ncmedboard.org/Clients/NCBOM/Public/ 
NewsandForum/mgmt.htm.  Last accessed January 24, 2007. 
7. Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canada--
prevalence, treatment, impact and the role of opioid analgesia.  Pain Res Manag. 2002 
Winter;7(4):179-84. 
8. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost 
due to common pain conditions in the US workforce.  JAMA. 2003 Nov 12;290(18):2443-54. 
9. National Institutes of Health.  Acupuncture. NIH Consensus Statement Online 1997 Nov 
3-5; 15(5):1-34.  Available at: http://consensus.nih.gov/1997/1997Acupuncture107html.htm.  
Last accessed: April 23, 2007. 
10. Rossi P, Di Lorenzo G, Faroni J, Malpezzi MG, Cesarino F, Nappi G.  Use of 
complementary and alternative medicine by patients with chronic tension-type headache: results 
of a headache clinic survey.  Headache. 2006 Apr;46(4):622-31. 
11. Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of 
oral morphine for chronic non-cancer pain.  Lancet. 1996 Jan 20;347(8995):143-7. 
12. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer 
pain: a meta-analysis of effectiveness and side effects.  CMAJ. 2006 May 23;174(11):1589-94. 
13. Martell BA, O'Connor PG, Kerns RD, et al.  Systematic review: opioid treatment for 
chronic back pain: prevalence, efficacy, and association with addiction.  Ann Intern Med. 2007 
Jan 16;146(2):116-27. 
 44 
14. Brown RT, Zuelsdorff M, Fleming M. Adverse effects and cognitive function among 
primary care patients taking opioids for chronic nonmalignant pain.  J Opioid Manag. 2006 May-
Jun;2(3):137-46. 
15. White JM.  Pleasure into pain: the consequences of long-term opioid use.  Addict Behav. 
2004 Sep;29(7):1311-24. 
16. Nicholson B.  Responsible prescribing of opioids for the management of chronic pain.  
Drugs. 2003;63(1):17-32. 
17. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al.  Predictors of opioid misuse in 
patients with chronic pain: a prospective cohort study.  BMC Health Serv Res. 2006 Apr 4;6:46. 
18. Kahan M, Srivastava A, Wilson L, Gourlay D, Midmer D. Misuse of and dependence on 
opioids: study of chronic pain patients.  Can Fam Physician. 2006 Sep;52(9):1081-7. 
19. McCabe S. E., Teter C. J., Boyd C. J., Knight J. R., Wechsler H. Non-medical use of 
prescription opioids among US college students: prevalence and correlates from a national 
survey. Addict Behav 2005; 30: 789–805. 
20. McCabe SE, West BT, Wechsler H.  Trends and college-level characteristics associated 
with the non-medical use of prescription drugs among US college students from 1993 to 2001.  
Addiction. 2007 Mar;102(3):455-65. 
21. Passik SD, Kirsh KL.  Opioid therapy in patients with a history of substance abuse.  CNS 
Drugs.  2004;18(1):13-25. 
22. Longo LP, Parran T Jr, Johnson B, Kinsey W.  Addiction: part II. Identification and 
management of the drug-seeking patient.  Am Fam Physician. 2000 Apr 15;61(8):2401-8. 
23. McNabb C, Foot C, Ting J, Breeze K, Stickley M.  Profiling patients suspected of drug 
seeking in an adult emergency department.  Emerg Med Australas. 2006 Apr;18(2):131-7. 
24. Quill TE.  Partnerships in patient care: a contractual approach. Ann Intern Med.  1983; 
98: 228–234. 
25. Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the 
management of chronic pain.  J Pain Symptom Manage. 1999 Jul;18(1):27-37. 
26. Adams NJ, Plane MB, Fleming MF, Mundt MP, Saunders LA, Stauffacher EA. Opioids 
and the treatment of chronic pain in a primary care sample.  J Pain Symptom Manage. 2001 
Sep;22(3):791-6. 
27. Michna E, Jamison RN, Pham LD, et al.  Urine toxicology screening among chronic pain 
patients on opioid therapy: frequency and predictability of abnormal findings.  Clin J Pain.  2007 
Feb;23(2):173-9. 
 45 
28. Katz NP, Sherburne S, Beach M, Rose RJ, Vielguth J, Bradley J, et al. Behavioral 
monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth 
Analg. 2003 Oct;97(4):1097-102, table of contents. 
29. Loder E. Who will prescribe? A proposal for specialized opioid management clinics.  
Pain Pract. 2003 Sep;3(3):218-21. 
30. Hasson AL, Grella CE, Rawson R, Anglin MD. Case management within a methadone 
maintenance program. A research demonstration project for HIV risk reduction.  J Case Manag. 
1994 Winter;3(4):167-72. 
31. Schneider JP.  Chronic pain management: evaluating the use of opioids.  Case Manager.  
1999 May-Jun; 10(3):61-6. 
32. Wells JC.  The place of the pain clinic.  Baillieres Clin Rheumatol. 1987 Apr;1(1):123-
53. 
33. Hudson JS, Pratt TH.  Pain clinics: their value to the general practitioner.  South Med J. 
1979 Jul;72(7):845-7. 
34. Fishman SM, Papazian JS, Gonzalez S, Riches PS, Gilson A. Regulating opioid 
prescribing through prescription monitoring programs: balancing drug diversion and treatment of 
pain.  Pain Med. 2004 Sep;5(3):309-24. 
35. Joranson DE, Carrow GM, Ryan KM, Schaefer L, Gilson AM, Good P, Eadie J, Peine S, 
Dahl JL. Pain management and prescription monitoring. J Pain Symptom Manage. 2002;23:231–
238. 
36. Simeone R, Holland L. An Evaluation of Prescription Drug Monitoring Programs (NCJ 
217269). Department of Justice: Washington DC, 2006. 
37. Haddox JD,  Joranson D, Angarola RT, et al.  The Use of Opioids for the Treatment of 
Chronic Pain: A consensus statement from the American Academy of Pain Medicine and the 
American Pain Society.  Available at: http://www.painmed.org/productpub/statements/ 
pdfs/opioids.pdf.  Last accessed June 1, 2007. 
38. American Medical Association.  About the AMA and Pain Management.  Available at: 
http://www.ama-assn.org/ama/pub/category/11541.html.  Last accessed June 1, 2007. 
39. Wilson PR.  ASA Statement to FDA Committee Opioid Use and Diversion: Report on 
Recent Hearings by FDA and DEA.  ASA Newsletter.  2002 Oct;66(10).  Available at 
http://www.asahq.org/Newsletters/2002/10_02/feature2.htm.  Last accessed June 1, 2007. 
40. Trescot AM, Boswell MV, Atluri SL, et al.  Opioid guidelines in the management of 
chronic non-cancer pain.  Pain Physician. 2006 Jan;9(1):1-39. 
41. Marcus DA.  Treatment of nonmalignant chronic pain.  Am Fam Physician. 2000 Mar 
1;61(5):1331-8, 1345-6. 
 46 
42. Steinbrook R.  Guidance for Guidelines.  New Engl J Med.  2007;356(4):331-333. 
43. Meier, Barry. Pain Killer: A "Wonder" Drug's Trail of Addiction and Death. USA: 
Rodale; 2003. 
44. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language 
bias in randomised controlled trials published in English and German. Lancet 1997;350: 326–29. 
45. Agency for Healthcare Research and Quality.  Systems to Rate the Strength of Scientific 
Evidence: Summary.  Available at:  http://www.ahrq.gov/clinic/epcsums/strengthsum.pdf.  Last 
accessed April 22, 2007. 
46. Hariharan J, Lamb GC, Neuner JM.  Long-term opioid contract use for chronic pain 
management in primary care practice: A five year experience.  J Gen Intern Med.  2007 
Apr;22(4):485-90. 
47. Manchikanti L, Manchukonda R, Damron KS, Brandon D, McManus CD, Cash K.  Does 
adherence monitoring reduce controlled substance abuse in chronic pain patients?  Pain 
Physician.  2006 Jan;9(1):57-60. 
48. Manchikanti L, Pampati V, Damron K.  Prevalence of prescription drug abuse and 
dependency in patients with chronic pain in western Kentucky.  J Ky Med Assoc.  2003;101:511-
517. 
49. Manchikanti L, Manchukonda R, Pampati V, et al.  Does random urine drug testing 
reduce illicit drug use in chronic pain patients receiving opioids?  Pain Physician.  2006 
Apr;9(2):123-9. 
50. Manchikanti L, Fellows B, Damron KS, Pampati V, McManus CD.  Prevalence of illicit 
drug use among individuals with chronic pain in the Commonwealth of Kentucky: An evaluation 
of patterns and trends.  J Ky Med Assoc.  2005; 103:55-62. 
51. Currie SR, Hodgins DC, Crabtree A, Jacobi J, Armstrong S.  Outcome from integrated 
pain management treatment for recovering substance abusers.  J Pain.  2003 Mar;4(2):91-100. 
52. Fishman SM, Mahajan G, Jung SW, Wilsey BL.  The trilateral opioid contract: Bridging 
the pain clinic and the primary care physician through the opioid contract.  J Pain Symptom 
Manage.  2002 Sep;24(3):335-44. 
53. Chelminski PR, Ives TJ, Felix KM, et al.  A primary care, multi-disciplinary disease 
management program for opioid-treated patients with chronic non-cancer pain and a high burden 
of psychiatric comorbidity.  BMC Health Serv Res.  2005 Jan 13;5(1):3. 
54. Chabal C, Erjavec MK, Jacobson L, Mariano A, Chaney E.  Prescription opiate abuse in 
chronic pain patients: clinical criteria, incidence, and predictors.  Clin J Pain.  1997 
Jun;13(2):150-5. 
 47 
55. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS.  Validity of self-reported drug use 
in chronic pain patients.  Clin J Pain.  1999 Sep;15(3):184-91. 
56. Manchikanti L, Damron KS, McManus CD, Barnhill RC.  Patterns of illicit drug use and 
opioid abuse in patients with chronic pain at initial evaluation: a prospective, observational 
study.  Pain Physician.  2004 Oct;7(4):431-7. 
57. Manchikanti L, Cash KA, Damron KS, Manchukonda R, Pampati V, McManus CD.  
Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of 
multiple variables.  Pain Physician.  2006 Jul;9(3):215-25.   
58. Jensen MK, Thomsen AB, Hojsted J.  10-year follow-up of chronic non-malignant pain 
patients: opioid use, health related quality of life and health care utilization.  Eur J Pain.  2006 
Jul;10(5):423-33. 
59. Kouyanou K, Pither CE, Wessely S.  Medication misuse, abuse and dependence in 
chronic pain patients.  J Psychosom Res. 1997 Nov;43(5):497-504. 
60. Becker N, Sjøgren P, Bech P, Olsen AK, Eriksen J.  Treatment outcome of chronic non-
malignant pain patients managed in a danish multidisciplinary pain centre compared to general 
practice: a randomised controlled trial.  Pain. 2000 Feb;84(2-3):203-11. 
61. McCracken LM, Evon D, Karapas ET.  Satisfaction with treatment for chronic pain in a 
specialty service: preliminary prospective results.  Eur J Pain. 2002;6(5):387-93. 
62. Cowan DT, Wilson-Barnett J, Griffiths P, Allan LG.  A survey of chronic noncancer pain 
patients prescribed opioid analgesics.  Pain Med.  2003 Dec;4(4):340-51. 
63. Fishbain DA, Lewis J, Cole B, et al.  Multidisciplinary pain facility treatment outcome 
for pain-associated fatigue.  Pain Med. 2005 Jul-Aug;6(4):299-304. 
64. Mahowald ML, Singh JA, Majeski P.  Opioid use by patients in an orthopedics spine 
clinic.  Arthritis Rheum.  2005 Jan;52(1):312-21. 
65. Højsted J, Nielsen PR, Eriksen J, Hansen OB, Sjøgren P.  Breakthrough pain in opioid-
treated chronic non-malignant pain patients referred to a multidisciplinary pain centre: a 
preliminary study.  Acta Anaesthesiol Scand. 2006 Nov;50(10):1290-6. 
66. Mercer SL, DeVinney BJ, Fine LJ, Green LW, Dougherty D.  Study designs for 
effectiveness and translation research :identifying trade-offs.  Am J Prev Med. 2007 
Aug;33(2):139-154. 
67. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United 
States. Am J Prev Med. 2006 Dec; 31(6)506-11. 
68. Yamaguchi R, Johnston LD, O'Malley PM.  Relationship between student illicit drug use 
and school drug-testing policies.  J Sch Health. 2003 Apr;73(4):159-64. 
 48 
69. American Civil Liberties Union.  Privacy in America: Workplace Drug Testing.  
Available at:  http://www.aclu.org/workplacerights/drugtesting/13394res19971231.html. Last 
accessed July 29, 2007. 
70. Meririnne E, Mykkänen S, Lillsunde P, et al.  Workplace drug testing in a military 
organization: Results and experiences from the testing program in the Finnish Defence Forces.  
Forensic Science International.  2007;170:171-174. 
71. Sorensen JL, Masson CL, Delucchi K, et al.  Randomized trial of drug abuse treatment-
linkage strategies.  J Consult Clin Psychol. 2005 Dec;73(6):1026-35. 
72. Laken MP, Ager JW. Effects of case management on retention in prenatal substance 
abuse treatment.  Am J Drug Alcohol Abuse. 1996 Aug;22(3):439-48. 
73. McLellan AT, Weinstein RL, Shen Q, Kendig C, Levine M. Improving continuity of care 
in a public addiction treatment system with clinical case management.  Am J Addict. 2005 Oct-
Dec;14(5):426-40. 
74. Fiellin DA, Pantalon MV, Chawarski MC, et al.  Counseling plus buprenorphine-
naloxone maintenance therapy for opioid dependence.  N Engl J Med. 2006 Jul 27;355(4):365-
74. 
75. Holmes CP, Gatchel RJ, Adams LL, et al.  An opioid screening instrument: long-term 
evaluation of the utility of the Pain Medication Questionnaire.  Pain Pract.  2006 Jun;6(2):74-88. 
76. Webster LR, Webster RM.  Predicting aberrant behaviors in opioid-treated patients: 
preliminary validation of the Opioid Risk Tool.  Pain Med.  2005 Nov-Dec;6(6):432-42. 
77. Wu SM, Compton P, Bolus R, et al.  The addiction behaviors checklist: validation of a 
new clinician-based measure of inappropriate opioid use in chronic pain.  J Pain Symptom 
Manage.  2006 Oct;32(4):342-51. 
78. Wallace JM.  The pharmacist’s role in managing chronic opioid therapy.  Curr Pain 
Headache Rep.  2006 Aug;10(4):245-52. 
79. Jennings PJ.  The role of the outpatient clinic nurse in monitoring opioid therapy.  Curr 
Pain Headache Rep.  2004 Aug;8(4):284-8. 
80. Leo RJ, Pristach CA, Streltzer J.  Incorporating pain management training into the 
psychiatry residency curriculum.  Acad Psychiatry.  2003 Spring;27(1):1-11. 
81. Bendtsen P, Hensing G, Ebeling C, Schedin A.  What are the qualities of dilemmas 
experienced when prescribing opioids in general practice?  Pain.  1999 Jul;82(1):89-96. 
82. Weinstein SM, Laux LF, Thornby JI, et al.  Medical students’ attitudes toward pain and 
the use of opioid analgesics: implications for changing medical school curriculum.  South Med J.  
2000 May;93(5):472-8. 
 49 
83. Brown D. Drug-related deaths hit 10-year low in Baltimore: greater funding, access to 
treatment credited. Washington Post. June 9, 2006:A10. Available at: 
http://www.washingtonpost.com/wp-dyn/content/article/2006/06/08/AR2006060801608.html. 
Last accessed June 2, 2006. 
84. Worthington N, Markham Piper T, Galea S, Rosenthal D. Opiate users’ knowledge about 




Tables and Figures: 
 
Figure 1.  Literature Search Flow Diagram 
 
  
Articles Reviewed in Detail—22 total 
 
3 Treatment Agreements 
10 Urine Drug Testing 
2 Case Management 
11 Pain Specialists 
2 Reporting Systems 
 
Articles Excluded Based on Title or Abstract Review 
 
 Reviews or Case 
 Editorials  Reports____ 
Treatment Agreements 12  0 
Urine Drug Testing 8  5 
Case Management 85  10 
Pain Specialists 57  11 
Reporting Systems 4  0 
 
Articles Included in Systematic Review—
5 total 
 
1 Treatment Agreements 
2 Urine Drug Testing 
0 Case Management 
1 Pain Specialists 
1 Reporting Systems 
 
Articles Identified in Electronic Searches 
for All Questions—332 total 
 
18 Treatment Agreements 
39 Urine Drug Testing 
156 Case Management 
166 Pain Specialists 
10 Reporting Systems 
Additional Articles Identified 
 
Expert Consultation  
1 Reporting Systems 
 
(No additional articles identified through 
reference list search) 
Articles Excluded After Detailed Review—19 total 
 
2 Treatment Agreements 
8 Urine Drug Testing 
2 Case Management 
10 Pain Specialists 
1 Reporting Systems 
 
Articles not in English 
 
0 Treatment Agreements 
1 Urine Drug Testing 
15 Case Management 
23 Pain Specialists 
0 Reporting Systems 
 
Studies Excluded Based on Title or Abstract Review 
 
 Different Intervention 
 or Population   
Treatment Agreements 3 
Urine Drug Testing 15 
Case Management 44 
Pain Specialists 64 
Reporting Systems 5 
 
 51 
Figure 2.  Opioid analgesic sales vs. unintentional & undetermined drug poisoning deaths by 
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